Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
MaxCyte ( (MXCT) ) has provided an update.
MaxCyte, Inc., a company in the biotechnology industry, has announced a change in the major holdings of its shares. The notification indicates that BlackRock, Inc. has acquired and now holds a total of 8.44% of MaxCyte’s voting rights, marking a slight decrease from the previous 8.52%. This adjustment reflects a minor shift in voting influence, potentially impacting strategic decisions and shareholder dynamics within the company.
More about MaxCyte
YTD Price Performance: -10.64%
Average Trading Volume: 44,487
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £345.1M
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- HRIF, HUV: 2 Canadian ETFs to Boost Your Portfolio Returns
- Alphabet’s Google Asks FTC to Break Microsoft-OpenAI Exclusive Deal
- Amazon Autos Starts Offering Hyundai Cars for Sale to Customers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
